Movement Alert｜SBP GROUP Rises 3.15% in Regular Trading, Continued Post-Earnings Momentum Supported by Analyst Upgrades

Market Focus

Aug 21

On August 21, SBP GROUP rose 3.15% in regular trading, trading at HK$5.555/share with turnover of HK$226 million, extending gains following its blockbuster H1 results released on August 19.

The continued upward momentum follows multiple analyst endorsements. BOCOM International maintained a Buy rating with a target price of HK$10 based on a DCF model, citing H1 revenue growth of 10.6% year-over-year to RMB 19.4 billion and adjusted net profit surging 92.3% to RMB 3.3 billion, which significantly exceeded market expectations. Citi also raised its target price to HK$10.8, highlighting innovative drug sales growth of 44.3% to RMB 8.79 billion. Gross margin improved to 83.0% while SG&A and R&D expense ratios declined materially to 32.0% and 17.0% respectively. Management guided that innovative drug revenue contribution would reach approximately 50% for the full year, with over 30 new innovative drugs expected to launch between now and 2030 with domestic peak sales potential of RMB 50 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1111305222"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111305222\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111305222?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-21 10:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111305222","market":"us","top_or_hot":-1,"title":"Movement Alert｜SBP GROUP Rises 3.15% in Regular Trading, Continued Post-Earnings Momentum Supported by Analyst Upgrades","media":"Market Focus","content":"<p><p>On August 21, SBP GROUP rose 3.15% in regular trading, trading at HK$5.555/share with turnover of HK$226 million, extending gains following its blockbuster H1 results released on August 19.</p><p>The continued upward momentum follows multiple analyst endorsements. BOCOM International maintained a Buy rating with a target price of HK$10 based on a DCF model, citing H1 revenue growth of 10.6% year-over-year to RMB 19.4 billion and adjusted net profit surging 92.3% to RMB 3.3 billion, which significantly exceeded market expectations. Citi also raised its target price to HK$10.8, highlighting innovative drug sales growth of 44.3% to RMB 8.79 billion. Gross margin improved to 83.0% while SG&A and R&D expense ratios declined materially to 32.0% and 17.0% respectively. Management guided that innovative drug revenue contribution would reach approximately 50% for the full year, with over 30 new innovative drugs expected to launch between now and 2030 with domestic peak sales potential of RMB 50 billion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜SBP GROUP Rises 3.15% in Regular Trading, Continued Post-Earnings Momentum Supported by Analyst Upgrades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜SBP GROUP Rises 3.15% in Regular Trading, Continued Post-Earnings Momentum Supported by Analyst Upgrades\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-21 10:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 21, SBP GROUP rose 3.15% in regular trading, trading at HK$5.555/share with turnover of HK$226 million, extending gains following its blockbuster H1 results released on August 19.</p><p>The continued upward momentum follows multiple analyst endorsements. BOCOM International maintained a Buy rating with a target price of HK$10 based on a DCF model, citing H1 revenue growth of 10.6% year-over-year to RMB 19.4 billion and adjusted net profit surging 92.3% to RMB 3.3 billion, which significantly exceeded market expectations. Citi also raised its target price to HK$10.8, highlighting innovative drug sales growth of 44.3% to RMB 8.79 billion. Gross margin improved to 83.0% while SG&A and R&D expense ratios declined materially to 32.0% and 17.0% respectively. Management guided that innovative drug revenue contribution would reach approximately 50% for the full year, with over 30 new innovative drugs expected to launch between now and 2030 with domestic peak sales potential of RMB 50 billion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1111305222","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111305222","pubTimestamp":1787279395,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 21, SBP GROUP rose 3.15% in regular trading, trading at HK$5.555/share with turnover of HK$226 million, extending gains following its blockbuster H1 results released on August 19.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"走势警报|SBP GROUP 在常规交易中上涨 3.15%，在分析师升级的支持下，财报后势头持续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"On August 21, SBP GROUP rose 3.15% in regular trading, trading at HK$5.555/share with turnover of HK$226 million, extending gains following its blockbuster H1 results released on August 19.The continued upward momentum follows multiple analyst endorsements. BOCOM International maintained a Buy rating with a target price of HK$10 based on a DCF model, citing H1 revenue growth of 10.6% year-over-year to RMB 19.4 billion and adjusted net profit surging 92.3% to RMB 3.3 billion, which significantly exceeded market expectations. Citi also raised its target price to HK$10.8, highlighting innovative drug sales growth of 44.3% to RMB 8.79 billion. Gross margin improved to 83.0% while SG&A and R&D expense ratios declined materially to 32.0% and 17.0% respectively. Management guided that innovative drug revenue contribution would reach approximately 50% for the full year, with over 30 new innovative drugs expected to launch between now and 2030 with domestic peak sales potential of RMB 50 billion.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}